Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Incyte

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval Drug approved for emergency use in combination with Gilead's remdesivir. Eli Lilly and Incyte’s arthritis treatment baricitinib has been repurposed as a COVID-19 treatment, scoring an emergency use

Switzerland: a life sciences hub

Switzerland: a life sciences hub American oncology specialist Incyte invested $100m for a monoclonal antibody production site in Yverdon (Vaud).

Incyte launches award programme recognising innovation in GVHD community

Incyte launches award programme recognising innovation in GVHD community have a devastating impact on the lives of patients,” said Barry Flannelly, executive vice president and general manager, US, Incyte. ... Through the Incyte Ingenuity Award, we hope to spark creativity and innovation, which we expect to result in

Incyte’s JAK inhibitor cream clears second eczema trial

Incyte’s JAK inhibitor cream clears second eczema trial Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... Incyte has said it intends to market ruxolitinib cream itself in

Novartis pulls ahead of Merck in MET-positive lung cancer race

Novartis pulls ahead of Merck in MET-positive lung cancer race Capmatinib – originally developed by Incyte and licensed to Novartis in 2009 – has been submitted for approval in the US for metastatic MET exon14 skipping-mutated NSCLC, a form of lung cancer

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...